FAS and ovarian carcinoma: Previous research has found that circSLC22A3 inhibits ovarian cancer progression by inducing Fas gene expression through sponge adsorption of the oncogenic factor miR-518a-5p, which provides a novel therapeutic approach for ovarian cancer [49].